Angelini Pharma, part of the privately-owned Angelini Holding, and Lumira Ventures today announced the launch of the Angelini Lumira Biosciences Fund (ALBF). The fund, which will be managed by Lumira Ventures, a leading North American life sciences venture capital firm, has been established to invest in early-stage companies in Canada and U.S. markets, that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases.
Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF)
Previous
Previous
University of Toronto spinout Deep Genomics raises US$180-million from Softbank, CPP, Fidelity to develop drugs discovered by AI
Next
Next